Clinical Trial Update: Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab with interleukin-12 in several B-cell non-Hodgkin lymphomas. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Interleukin-12 (interleukin-12)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Status: COMPLETED